Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7759/cureus.10211 http://scihub22266oqcxt.onion/10.7759/cureus.10211 33033686!7532870!33033686     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cureus 2020 ; 12 (9): e10211 Nephropedia Template TP {{tp|p=33033686|t=2020. Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection |pdf=|usr=}}{{33033686}} gab.com Text Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection JO: Cureus http://www.kidney.de/pget.php?&tw=1&pmid=33033686 #FOAvip COVID-19 is a fatal, universal pandemic caused by the SARS-CoV-2 virus that has directly caused at least 95,235 deaths in the US by May 2020. It has a poor prognosis with a mortality rate as high as 21% in the general population at the height of the pandemic, a rate that is much higher in elderly patients, as well as those requiring intensive care unit (ICU) care. The role of inflammation in symptomatic COVID-19 is being studied, and it is hypothesized that hyper-inflammation is a causative factor in severe COVID-19 disease. Treatment options are limited and mostly rely on supportive care. Icosapent ethyl (IPE) is an Omega-3 fatty acid derivative that has been shown to significantly reduce cardiovascular mortality and is used as an adjunct to statin therapy. Though it has been shown to act as an anti-inflammatory, it is not currently indicated for that purpose. Here, we describe, for the first time, the successful treatment of a COVID-19 patient with IPE. Twit Text FOAVip Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection ????Cureus http://www.kidney.de/pget.php?&tw=1&pmid=33033686 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33033686 #FOAvip English Wikipedia <ref>{{Cite pmid|33033686}}</ref> Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection #MMPMID33033686 Berger AA; Sherburne R; Urits I; Patel H; Eskander J Cureus 2020[Sep]; 12 (9): e10211 PMID33033686show ga COVID-19 is a fatal, universal pandemic caused by the SARS-CoV-2 virus that has directly caused at least 95,235 deaths in the US by May 2020. It has a poor prognosis with a mortality rate as high as 21% in the general population at the height of the pandemic, a rate that is much higher in elderly patients, as well as those requiring intensive care unit (ICU) care. The role of inflammation in symptomatic COVID-19 is being studied, and it is hypothesized that hyper-inflammation is a causative factor in severe COVID-19 disease. Treatment options are limited and mostly rely on supportive care. Icosapent ethyl (IPE) is an Omega-3 fatty acid derivative that has been shown to significantly reduce cardiovascular mortality and is used as an adjunct to statin therapy. Though it has been shown to act as an anti-inflammatory, it is not currently indicated for that purpose. Here, we describe, for the first time, the successful treatment of a COVID-19 patient with IPE. äIcosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infe(epmc).pdf DeepDyve Pubget Overpricing